Traian B.
- Country
- Romania
- Department
- Psihiatrie
Research Overview
- Evaluation of Valbenazine as Adjunctive Therapy in Schizophrenia Patients with Inadequate Antipsychotic Response: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial
- Efficacy and Safety Evaluation of Lumateperone in Acute Treatment of Manic Episodes in Bipolar I Disorder: A Randomized, Double-Blind, Placebo-Controlled Study
- Efficacy and Safety Evaluation of Ulotaront (SEP-363856) in Acutely Psychotic Schizophrenia Patients: A Randomized, Double-Blind, Placebo-Controlled Study
Data & Insights
Has run more than one trial at 73 of 202 partner sites.
Specializations
Psychotic Disorders
Investigation of acute and chronic manifestations of severe mental illness with emphasis on symptom reduction and functional improvement.
- Acute schizophrenia
- Psychosis associated with Alzheimer’s disease
- Adjunctive antipsychotic strategies
Focus on scalable outcomes measured by standardized rating scales.
Mood Disorders
Targeted studies of depressive and manic episodes to refine therapeutic options.
- Manic episodes in bipolar I disorder
- Major depressive disorder with anhedonia
- Adjunctive treatments for treatment‑resistant mood states
Emphasis on rapid symptom control and relapse prevention.
Alzheimer’s Disease Behavioral Symptoms
Clinical programs addressing neuropsychiatric complications in dementia populations.
- Agitation associated with Alzheimer’s dementia
- Psychosis in Alzheimer’s disease
- Combination therapies for behavioral management
Utilizes caregiver‑reported scales to evaluate efficacy.
Adjunctive Pharmacologic Strategies
Evaluation of add‑on agents designed to augment standard psychiatric regimens.
- Adjunctive valbenazine in schizophrenia
- Adjunctive aticaprant in major depressive disorder
- Adjunctive KarXT in bipolar mania
Studies prioritize safety alongside symptomatic benefit.
Long‑Term Safety and Tolerability
Extended observation of investigational compounds to determine chronic risk profiles.
- Long‑term safety of NBI‑1117568 in schizophrenia
- Extended tolerability of azetukalner in depression
- Durability of response with KarXT + KarX‑EC in Alzheimer’s agitation
Data support regulatory submissions and clinical guideline development.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.